Cart
sales@molnova.com
Bromo-PEG3-C2-acid
CAS No. 782475-35-8
Bromo-PEG3-C2-acid( —— )
Catalog No. M24782 CAS No. 782475-35-8
Bromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 26 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBromo-PEG3-C2-acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionBromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
DescriptionBromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number782475-35-8
-
Formula Weight285.13
-
Molecular FormulaC9H17BrO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)CCOCCOCCOCCBr
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
-
MZ1
MZ1 is a?PROTAC that tethers JQ1 to a ligand for the E3 ubiquitin ligase VHL, triggers, induces degradation of the BET bromodomain BRD4.
-
Lenalidomide-Br
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
-
ARV-771
ARV-771, a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.
